% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by skylesa Dec 8, 2014 9:16 AM

    are they burying the CVR's in a paper shuffle? Had difficulty trying to get any info on them.

  • The terms of the non-tradable CVR include an additional payment of up to $2.00 if certain sales milestones are achieved. The CVR will entitle each Trius stockholder to receive $1.00 per share if net sales of tedizolid in the U.S., Canada and Europe are greater than or equal to $125 million in 2016 and up to an additional $1.00 per share, paid on a pro rata basis, for 2016 net sales between $125 million and $135 million.
    Barclays is acting as the exclusive financial advisor to Cubist, and Ropes & Gray LLP is serving as its legal counsel. Citi and Centerview Partners LLC are acting as financial advisors to Trius, and Cooley LLP is serving as its legal counsel.

Must Watch